Regardless of the sequential decrease in Current Liabilities, during the third quarter 2025, Quick Ratio deteriorated to 17.11 above company average Quick Ratio.

Within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Quick Ratio than Ventyx Biosciences Inc in third quarter 2025. While Quick Ratio total ranking has improved so far during the Q3 2025 to 132, from total ranking in the second quarter 2025 at 133.

Explain Quick Ratio?
How much Cash & cash equivalents VTYX�s has?
What are VTYX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

VTYX Quick Ratio	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3
Y / Y Current Liabilities Change	-8.49 %	-36.65 %	-14.72 %	-42.62 %	-53.06 %
Y / Y Cash & cash equivalent Change	-29.91 %	-12.73 %	-24.38 %	-13.84 %	-8.64 %
Quick Ratio MRQ	17.11	18.22	18.46	17.01	22.34
VTYX's Total Ranking	# 132	# 133	# 80	# 73	# 85
Seq. Current Liabilities Change	-1.83 %	-7.46 %	-2.99 %	3.84 %	-32.04 %
Seq. Cash & cash equivalent Change	-7.81 %	-8.67 %	5.28 %	-20.92 %	14.78 %

Quick Ratio third quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 35
Healthcare Sector	# 52
Overall Market	# 132

Quick Ratio Statistics
High	Average	Low
22.82	16.58	11.33
(Mar 31 2023)		(Dec 31 2023)

Financial Statements
Ventyx Biosciences Inc 's Current Liabilities	$ 11 Millions	Visit VTYX's Balance sheet
Ventyx Biosciences Inc 's Cash & cash equivalent	$ 193 Millions	Visit VTYX's Balance sheet
Source of VTYX's Sales		Visit VTYX's Sales by Geography

Cumulative Ventyx Biosciences Inc 's Quick Ratio

VTYX's Quick Ratio for the trailling 12 Months

VTYX Quick Ratio	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-28.73 %	-39.66 %	-33.07 %	-32.12 %	-15.05 %
Y / Y Cash & cash equivalent TTM Growth	-20.7 %	-15.08 %	-19.15 %	-18.07 %	-19.49 %
Quick Ratio TTM	17.7	19	17.28	17.92	15.91
Total Ranking TTM	# 1894	# 2315	# 2100	# 2572	# 1915
Seq. Current Liabilities TTM Growth	-2.13 %	-11.94 %	-3.71 %	-14.12 %	-17.14 %
Seq. Cash & cash equivalent TTM Growth	-8.84 %	-3.17 %	-7.13 %	-3.26 %	-2.37 %

Quick ratio ranking by company, industry and sector >> Back to VTYX Financial Strength Comparisons >> Go to Compare VTYX Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in VTYX's Current Liabilities to $11.26 millions, cumulative Quick Ratio to 17.7 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 326 other companies have achieved higher Quick Ratio than Ventyx Biosciences Inc . While Quick Ratio overall ranking has improved so far to 1894, from total ranking during the twelve months ending second quarter 2025 at 2315.

Explain Quick Ratio?
How much Cash & cash equivalents VTYX�s has?
What are VTYX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 327
Healthcare Sector	# 657
Within the Market	# 1894

trailing twelve months Quick Ratio Statistics
High	Average	Low
19	15.65	12.09
(Jun 30 2025)		(Mar 31 2022)

Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2025 MRQ Cash & cash equivalent	Sep 30 2025 MRQ Current Liabilities
Curanex Pharmaceuticals Inc	46.70	$ 5.831 Millions	$ 0.125 Millions
Altimmune inc	43.88	$ 210.776 Millions	$ 4.804 Millions
Xbiotech Inc	41.34	$ 147.367 Millions	$ 3.565 Millions
Belite Bio Inc	36.61	$ 352.932 Millions	$ 9.641 Millions
Rapport Therapeutics Inc	35.84	$ 513.026 Millions	$ 14.316 Millions
Bright Minds Biosciences Inc	35.59	$ 63.669 Millions	$ 1.789 Millions
Janux Therapeutics Inc	35.54	$ 988.993 Millions	$ 27.831 Millions
Inhibitor Therapeutics Inc	34.01	$ 2.977 Millions	$ 0.088 Millions
Disc Medicine Inc	33.50	$ 615.920 Millions	$ 18.383 Millions
Roivant Sciences Ltd	32.77	$ 4,385.835 Millions	$ 133.857 Millions
Mbx Biosciences Inc	32.47	$ 391.673 Millions	$ 12.062 Millions
Upstream Bio Inc	31.28	$ 372.427 Millions	$ 11.908 Millions
Repare Therapeutics Inc	30.54	$ 112.604 Millions	$ 3.687 Millions
Keros Therapeutics Inc	28.78	$ 693.472 Millions	$ 24.092 Millions
Contineum Therapeutics Inc	28.68	$ 182.407 Millions	$ 6.361 Millions
Viking Therapeutics Inc	27.88	$ 714.570 Millions	$ 25.630 Millions
Liquidia Corporation	26.17	$ 157.496 Millions	$ 6.019 Millions
Edgewise Therapeutics inc	26.03	$ 563.340 Millions	$ 21.646 Millions
Prothena Corporation Public Limited Company	25.09	$ 330.843 Millions	$ 13.188 Millions
Immuneering Corporation	24.83	$ 227.563 Millions	$ 9.164 Millions
Psyence Biomedical ltd	23.53	$ 7.150 Millions	$ 0.304 Millions
Lava Therapeutics Nv	23.48	$ 99.364 Millions	$ 4.231 Millions
Trevi Therapeutics Inc	22.29	$ 194.927 Millions	$ 8.745 Millions
Ligand Pharmaceuticals Incorporated	21.76	$ 664.522 Millions	$ 30.539 Millions
Aprea Therapeutics Inc	21.39	$ 13.718 Millions	$ 0.641 Millions
Stoke Therapeutics Inc	21.34	$ 248.310 Millions	$ 11.634 Millions
Cervomed Inc	20.23	$ 27.294 Millions	$ 1.349 Millions
Pulmatrix Inc	19.25	$ 4.794 Millions	$ 0.249 Millions
Terns Pharmaceuticals Inc	19.21	$ 295.635 Millions	$ 15.387 Millions
Emmis Acquisition Corp	18.63	$ 1.446 Millions	$ 0.078 Millions

Date modified: 2026-08-29T17:46:00+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.